A Crossover Pilot Study of the Effect of Amiloride on Proteinuria (NCT02522650) | Clinical Trial Compass
UnknownPhase 4
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria
United States30 participantsStarted 2013-07
Plain-language summary
This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient with any type of proteinuric kidney diseases
* Aged 18-75
* Proteinuria ≥1g/day
* estimated glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m2
Exclusion Criteria:
* Clinical evidences of lupus nephritis, or HIV associated nephropathy
* eGFR \<30ml/min/1.73m2
* Requirement for treatment with mineralocorticoid receptor antagonists (spironolactone, eplerenone)
* Status post kidney transplant
* Received glucocorticoid steroids within six months
* Serum K \>4.8 mmol/L
* Total carbon dioxide \<17 mmol/L
* Hemoglobin \<10 g/dl
* Contraindicated or allergic to loop diuretics or potassium sparing diuretics
* Abnormal liver function tests